THE DEAL, AT A GLANCE

Altay Therapeutics

2/4 reviewed

Altay Therapeutics

Altay develops oral drug candidates for muscular dystrophy, cancer and chronic inflammatory diseases.

Altay Therapeutics raised $37M Series A, announced 2026-10-14

01What it doesAltay develops oral drug candidates for muscular dystrophy, cancer and chronic inflammatory diseases.Source-grounded · automated review · Explore ↗

Checked 2026-10-14 · Review due 2026-10-21

Read supporting source ↗

Our pipeline includes the first…

02What happenedAltay Therapeutics raised $37M Series A, announced 2026-10-14From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03Why it mattersIts lead drug aims to make a serious muscular dystrophy treatment easier to take and deliver.Interpretation · Explore ↗

Checked 2026-10-14 · Review due 2026-10-21

Read supporting source ↗

Our lead program targets DUX4,…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

Altay Therapeutics · Financing Record

Explore source-linked visual explanations for Altay Therapeutics. Unsupported claims are withheld while source review continues.

Record 14042 · Recorded date: 2026-10-14

What it does

Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.

Open record 14042 →